Pasithea Therapeutics
KTTA
10 hedge funds and large institutions have $662K invested in Pasithea Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
25% more funds holding
Funds holding: 8 → 10 (+2)
0.64% less ownership
Funds ownership: 3.46% → 2.82% (-0.64%)
56% less capital inflows, than outflows
Capital inflows: $113K | Capital outflows: $257K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
| 4 |
Virtu Financial
New York
|
+$15.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$95K |
| 2 |
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
|
-$62K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$61.9K |
| 4 |
Two Sigma Securities
New York
|
-$25K |
| 5 |
BlackRock
New York
|
-$13K |
KTTA Hedge Fund Activity: Q2 2022 in Review
10 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2022, worth a combined $662K — down 33% from $985K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KTTA positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $25.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $95K sold.
- 10 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2022, up from 8 in Q1 2022.
- Funds reported $662K of Pasithea Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
- 6 funds opened new Pasithea Therapeutics positions in Q2 2022 and 4 closed out, a net change of +2 holders.
- The largest Pasithea Therapeutics buyer in Q2 2022 was State Street, an estimated $25.2K added.
- The largest Pasithea Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $95K sold.
Based on aggregated 13F filings for Q2 2022.